Keith Webber, Ph.D., new Vice President, Biotechnology at Lachman Consultant Services, Inc.

We are pleased to announce that Keith Webber, Ph.D. has accepted the position of Vice President, Biotechnology at Lachman Consultants, effective September 1, 2018.

Dr. Webber delivers scientific direction, strategic guidance, and leadership regarding biotechnology products, new drugs, and generic drugs, based on his 30+ years of combined industry, U.S. FDA, and NIH experience.  His expertise is inclusive of products that encompass both naturally-derived as well as recombinant products. Dr. Webber is an expert in biological chemistry, enzymology, lipid chemistry, molecular biology, regulatory affairs, and FDA policies and procedures.

Prior to joining Lachman Consultants, Dr. Webber served as Senior Director of Rx Regulatory Affairs for Perrigo Company as well as 18 years at the U.S. FDA where he held several senior-level positions in both CDER and CBER, including Director, Office of Pharmaceutical Science (OPS)/CDER; Director, Office of Generic Drugs/CDER; Deputy Director, OPS/CDER; Director, Office of Biotechnology Products/CDER; and Director, Division of Monoclonal Antibodies/CBER.  He also held research positions in molecular biology and protein engineering at NIH.

Dr. Webber earned his Ph.D. in Biological Chemistry from the University of Michigan and his B.S. in Chemistry from the University of Denver.

For four decades, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available.  Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutions based on the integration of scientific principles, evolving regulatory expectations, and technology.